Plasma and Salivary 6β-Hydroxycortisol Measurements for Assessing Adrenocortical Activity in Patients with Adrenocortical Adenomas

Abstract

The aim of this study was to examine and compare the potential usefulness of plasma and salivary 6β-hydroxycortisol measurements for assessing adrenocortical activity in patients with adrenocortical adenomas. Plasma and salivary cortisol as well as 6β-hydroxycortisol determinations were performed by radioimmunoassay after extraction with ethyl acetate followed by chromatographic separation using a modified paper chromatographic system. Samples were obtained from 36 control subjects and 37 patients with non-hyperfunctioning adrenocortical adenomas in the morning at 8 a. m. after a low-dose of dexamethasone and after stimulation with synthetic depot ACTH. Basal and post-dexamethasone hormone levels were also measured in plasma and salivary samples of 4 patients with Cushing's syndrome from adrenal adenomas. In the baseline state, patients with non-hyperfunctioning adrenocortical adenomas had significantly higher plasma and salivary 6β-hydroxycortisol levels (mean ± SE, 79.0 ± 7 and 17.1 ± 2.2 ng/dl, respectively) compared to those measured in controls (62.0 ± 4 and 7.7 ± 0.6 ng/dl, respectively), whereas baseline plasma and salivary cortisol levels (9.6 ± 0.5 µg/dl and 342 ± 39 ng/dl, respectively) were similar to those measured in the control group (9.9 ± 0.4 µg/dl and 366 ± 24 ng/dl, respectively). In all groups, the changes in plasma and salivary 6β-hydroxycortisol concentrations after dexamethasone suppression and ACTH stimulation were similar to the changes in plasma and salivary cortisol levels, although the differing ratios of 6βOHF to cortisol indicated potentially important variations in the induction of 6β-hydroxylase activity between the three groups. In patients with Cushing's syndrome, baseline plasma and salivary 6β-hydroxycortisol concentrations (754 ± 444 and 104 ± 88 ng/dl, respectively) were more markedly increased than plasma and salivary cortisol levels (24.8 ± 6.7 µg/dl and 1100 ± 184 ng/dl, respectively), and all remained non-suppressible after dexamethasone administration. These results suggests that plasma and salivary 6β-hydroxycortisol determinations may precisely detect not only overt increases of cortisol secretion in patients with Cushing's syndrome but also mild glucocorticoid overproduction presumably present in patients with non-hyperfunctioning adrenocortical tumors.

Cushing's syndrome - Non-hyperfunctioning adrenocortical adenoma - Cortisol metabolism - ACTH - Dexamethasone

References

• 1 Vining R F, McGinley R A, Maksvytis J J, Ho K Y. Salivary cortisol: a better measure of adrenal cortical functions than serum cortisol.  Ann Clin Biochem. 1983;  20 329-335
• 2 Aardal-Eriksson E, Karlberg B E, Holm A-C. Salivary cortisol - an alternative to serum cortisol determination in dynamic function tests.  Clin Chem Lab Med. 1998;  36 215-222
• 3 Barrou Z, Guiban D, Maroufi A, Fournier C, Dugué M A, Luton J P, Thomopoulos P. Overnight dexamethasone suppression test: comparison of plasma and salivary cortisol measurement for the screening of Cushing's syndrome.  Eur J Endocrinol. 1996;  134 93-96
• 4 Laudat M H, Cerdas S, Fournier C, Guiban B, Guilhaume B, Luton J P. Salivary cortisol measurement: a practical approach to assess pituitary-adrenal function.  J Clin Endocrinol. Metab1988;  66 343-348
• 5 Francis S J, Walker R F, Riad-Fahmy D, Hughes D, Murphy J F, Gray O P. Assessment of adrenocortical activity in term newborn infants using salivary cortisol determinations.  J Pediatrics. 1987;  111 129-133
• 6 Antonini S RR, Jorge S M, Moreira A C. The emergence of salivary cortisol circadian rhythm and its relationship to sleep activity in preterm infants.  Clin Endocrinol. 2000;  52 423-426
• 7 Martinelli C E, Sader S L, Oliveira E B, Daneluzzi J C, Moreira A C. Salivary cortisol for screening of Cushing's syndrome in children.  Clin Endocrinol. 1999;  51 67-71
• 8 Nelson N, Arbring K, Theodorsson E. Neonatal salivary cortisol in response to heelstick: method modifications enable analysis of low concentrations and small sample volumes.  Scand J Clin Lab Invest. 2001;  61 287-291
• 9 Luthold W W, Marcondes J AM, Wajchenberg B L. Salivary cortisol for the evaluation of Cushing's syndrome.  Clin Chim Acta. 1985;  151 33-39
• 10 Raff H, Raff J L, Findling J W. Late-night salivary cortisol as a screening test for Cushing's syndrome.  J Clin Endocrinol Metab. 1998;  83 2681-2686
• 11 Strickland P, Morris A, Wearden A, Deakin B. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls.  J Affect Dis. 1998;  47 191-194
• 12 Castro M, Elias P CL, Quidute A RP, Halah F PB, Moreira A C. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests.  J Clin Endocrinol Metab. 1999;  84 878-882
• 13 Immanuel C, Sarma G R, Krishnamurthy P V, Ramachandran G, Kumaraswami V. Salivary cortisol in the assessment of adrenocortical functions in patients with pulmonary tuberculosis.  Indian J Med Res (A). 1992;  95 1-7
• 14 Hucklebridge F, Sen S, Evans P D, Clow A. The relationship between circadian patterns of salivary cortisol and endogenous inhibitor monoamine oxidase A.  Life Sci. 1998;  62 2321-2328
• 15 Lipman M M, Katz F H, Jailer J W. An alternative pathway for cortisol metabolism: 6β-hydroxycortisol production by human tissue slices.  J Clin Endocrinol Metab. 1962;  22 268-272
• 16 Burstein S, Dorfman R I, Nadel E M. 6-beta-hydroxycortisol - a new steroid in human urine.  Arch Biochem and Biophys. 1954;  53 307-312
• 17 Katz F H, Lipman M M, Frantz A G, Jailer J W. The physiologic significance of 6β-hydroxycortisol in human corticoid metabolism.  J Clin Endocrinol Metab. 1962;  22 71-77
• 18 Bienvenu T, Rey E, Pons G, Athis P D, Olive G. A simple non-invasive procedure for the investigation pf cytochrome P-450 IIIA dependent enzymes in human.  Int J Clin Pharmacol Ther Toxicol. 1991;  29 441-445
• 19 Hunter D JS, Keane P, Walker W HC, YoungLai E V. Variations in urinary levels of free 6β-hydroxycortisol, cortisol and estrogens in late pregnancy.  Gynecol Obstet Invest. 1984;  18 83-87
• 20 Patel S B, Toddywalla V S, Betrabet S S, Kulharni R D, Kombo I, Saxena B N. Age related changes in urinary 6-beta hydroxycortisol in normal infants.  Indian Pediatr. 1996;  33 398-401
• 21 Voccia E, Saenger P, Peterson R E, Rauh W, Gottesdiener K, Levine L S, New M I. 6β-hydroxycortisol excretion in hypercortisolemic states.  J Clin Endocrinol Metab. 1979;  48 467-471
• 22 Edwards O M, Courtenay-Evans R J, Galles J M, Hunter J, Tait A D. Changes in cortisol metabolism following rifampicin therapy.  Lancet. 1974;  2 549-551
• 23 Saenger P, Forster E, Kream J. 6β-hydroxycortisol: a non-invasive indicator of enzyme induction.  J Clin Endocrinol Metab. 1981;  52 381-384
• 24 Moreland T A, Park B K, Rylance G W. Microsomal enzyme induction in children: the influence of carbamazepine treatment on antipyrine kinetics, 6-beta-hydroxycortisol excretion and plasma gamma-glutamyltranspeptidase activity.  Br J Clin Pharmacol. 1982;  14 861-865
• 25 Burstein S, Kimball H I, Klaiber E L, Gut M. Metabolism of 2-alpha- and 6β-hydroxycortisol in man: determination of production rates of 6β-hydroxycortisol with and without phenobarbital administration.  J Clin Endocrinol Metab. 1967;  27 491-499
• 26 Fukushima D K, Bradlow H L, Hellman L. Effects of o,p'-DDD on cortisol and 6β-hydroxycortisol secretion and metabolism in man.  J Clin Endocr. 1971;  32 192-200
• 27 Nahoul K, Adeline J, Paysant J, Scholler R. Radioimmunoassay of plasma and urine 6β-hydroxycortisol: levels in healthy adults and in hypercortisolemic states.  J Steroid Biochem. 1982;  17 343-350
• 28 Nakamura J, Minoru Y. Assessing adrenocortical activity by determining levels of urinary free cortisol and urinary 6β-hydroxycortisol.  Acta Endocrinol (Copenh). 1989;  120 277-283
• 29 Kishida S, Fukushima D K. Radioimmunoassay of 6β-hydroxycortisol in human plasma and urine. Steroids.  1977;  30 741-749
• 30 Vecsei P, Onyechi J, Hornung J, Dietz R, Mast G, Hobler H. Use of corticosteroid antibodies for the study of corticosteroid biosynthesis in vitro.  J Steroid Biochem. 1975;  6 383-387
• 31 Conolly T M, Vecsei P. Simple radioimmunoassay of cortisol in diluted samples of human plasma.  Clin Chem. 1978;  24 1466-1472
• 32 Park B K. Assessment of urinary 6β-hydroxycortisol as an in vivo index of mixed function oxygenase activity.  Br J Clin Pharmac. 1981;  12 97-102
• 33 Touchstone J C, Kasparow M, Rosenthal O. Most polar steroids of human adrenal incubates.  Fed Proc. 1959;  18 340
• 34 Gláz E, Rácz K, Varga I, Kiss R, Tóth M, Fütö L. Mineralocorticoid production of adrenal cortical adenomas.  J Steroid Biochem. 1993;  45 57-64
• 35 Ambrosi B, Peverelli S, Passini E. Re T, Ferrario R, Colombo P. Abnormalities of endocrine function in patients with clinically ‘silent' adrenal masses.  Eur J Endocrinol. 1995;  132 22-428
• 36 Tóth M, Rácz K, Varga I, Adleff V, Jakab C, Fütö L, Kiss R, Gláz E. Plasma dehydroepiandrosterone sulfate levels in patients with hyperfunctioning and non-hyperfunctioning adrenal tumors before and after adrenal surgery.  Eur J Endocrinol. 1997;  136 290-295
• 37 Reincke M, Nieke J, Krestin G P, Saeger W, Allolio B, Winkelmann W. Preclinical Cushing's syndrome in adrenal ”incidentalomas”: comparison with adrenal Cushing's syndrome.  J Clin Endocrinol Metab. 1992;  75 826-832
• 38 Ross N S. Epidemiology of Cushing's syndrome and subclinical disease.  Endocrinol Metab Clin North Am. 1994;  23 539-546
• 39 Tersolo M, Osella G, Ali A, Borretta G, Cesario F, Paccotti P, Angeli A. Subclinical Cushing's syndrome in adrenal incidentalomas.  Clin Endocrinol (Oxf). 1998;  48 89-97
• 40 Zhiri A, Mayer H A, Michaux V, Wellman-Bednawska M, Slest G. 6β-hydroxycortisol in serum and urine determined by enzyme immunoassay on microtitre plates.  Clin Chem. 1986;  30 2094-2097
• 41 Park B K. A direct radioimmunoassay for 6β-hydroxycortisol in human urine.  J Steroid Biochem,. 1978;  9 963-966
• 42 Ng M CY, Young R P, Critchley J AJH, Leung N WY, Lau J WY, Li A KC. Urinary 6β-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases.  Cancer,. 1996;  77 1427-1433
• 43 Tang C, Kassahun K, McIntosh I S, Brunner J, Rodrigues A D. Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by liquid chromatography - atmospheric pressure chemical ionization tandem mass spectrometry and its application for estimating hepatic CYP3A induction.  J Chromatogr B. 2000;  742 303-313
• 44 Furukori Y N, Kondo T, Kubota T, Otake H, Ohkubo T, Nagasaki T, Sugawara K, Chiba K, Otani K, Kaneko S. No correlations between the urinary ratio of 6 beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam.  Eur J Clin Pharmacol. 2001;  57 285-288